CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
26. November 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Participate in the Piper Sandler 36th Annual Healthcare Conference. Management holding one-on-one meetings with investors
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
07. November 2024 16:05 ET
|
CytoSorbents
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
04. November 2024 07:00 ET
|
CytoSorbents
CytoSorbents submits DrugSorb-ATR Medical Device License Application to Health Canada following MDSAP Certification. Expects regulatory decision in 2025
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
22. Oktober 2024 07:00 ET
|
CytoSorbents
FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
17. Oktober 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Announce Q3 2024 Financial and Operating Results on November 7, 2024
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
01. Oktober 2024 07:00 ET
|
CytoSorbents
CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
27. August 2024 07:00 ET
|
CytoSorbents
PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
13. August 2024 16:19 ET
|
CytoSorbents
New CFO Peter J. Mariani to succeed retiring CFO Kathleen P. BlochOn track for DrugSorb™-ATR U.S. FDA De Novo and Health Canada marketing submissions this quarterIn Q2 2024, increased product sales by...
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
13. August 2024 16:18 ET
|
CytoSorbents
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
07. August 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Report Q2 2024 Financial and Operating Results